GlycoMimetics Inc (GLYC)
0.402
+0.01
(+1.64%)
USD |
NASDAQ |
Nov 13, 16:00
0.405
0.00 (0.00%)
After-Hours: 20:00
GlycoMimetics Cash from Financing (Quarterly): 0.0005M for June 30, 2024
Cash from Financing (Quarterly) Chart
Historical Cash from Financing (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2024 | 0.0005M |
| March 31, 2024 | 0.0049M |
| December 31, 2023 | 0.001M |
| September 30, 2023 | 0.0616M |
| June 30, 2023 | 0.0201M |
| March 31, 2023 | 28.74M |
| December 31, 2022 | 4.157M |
| September 30, 2022 | 0.00 |
| June 30, 2022 | 0.00 |
| March 31, 2022 | 0.00 |
| December 31, 2021 | 1.140M |
| September 30, 2021 | 0.0208M |
| June 30, 2021 | 0.00 |
| March 31, 2021 | 9.564M |
| December 31, 2020 | 3.889M |
| September 30, 2020 | 4.545M |
| June 30, 2020 | 9.580M |
| March 31, 2020 | 0.13M |
| December 31, 2019 | 0.1198M |
| September 30, 2019 | 0.1868M |
| June 30, 2019 | 0.0758M |
| March 31, 2019 | 0.0306M |
| December 31, 2018 | 0.126M |
| Date | Value |
|---|---|
| September 30, 2018 | 0.5048M |
| June 30, 2018 | -0.1139M |
| March 31, 2018 | 128.93M |
| December 31, 2017 | 19.46M |
| September 30, 2017 | -0.0128M |
| June 30, 2017 | 90.83M |
| March 31, 2017 | 3.674M |
| December 31, 2016 | 1.152M |
| September 30, 2016 | -0.1053M |
| June 30, 2016 | 21.35M |
| March 31, 2016 | 1.274M |
| December 31, 2015 | 0.0034M |
| September 30, 2015 | 0.0202M |
| June 30, 2015 | 0.0152M |
| March 31, 2015 | 0.0754M |
| December 31, 2014 | 0.0062M |
| September 30, 2014 | 0.0004M |
| June 30, 2014 | 0.1195M |
| March 31, 2014 | 57.26M |
| December 31, 2013 | 0.1991M |
| September 30, 2013 | 0.3401M |
| June 30, 2013 | 0.0198M |
| March 31, 2013 | 0.00 |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (Quarterly) Range, Past 5 Years
--
Minimum
Jun 2021
28.74M
Maximum
Mar 2023
3.262M
Average
0.0616M
Median
Sep 2023
Cash from Financing (Quarterly) Benchmarks
| Biomarin Pharmaceutical Inc | -499.12M |
| Arbutus Biopharma Corp | 1.775M |
| Revance Therapeutics Inc | -6.087M |
| FibroGen Inc | 0.032M |
| Cidara Therapeutics Inc | 239.13M |
Cash from Financing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -8.893M |
| Cash from Investing (Quarterly) | -0.0025M |
| Free Cash Flow | -35.72M |
| Free Cash Flow Per Share (Quarterly) | -0.138 |
| Free Cash Flow Yield | -137.9% |